In conclusion, our data demonstrated that the HER2‐targeting CD40 BsAb could achieve localised activation of CD40 in tumours while simultaneously minimising the toxicity associated with systemic CD40 activation, thereby addressing the challenges encountered in current clinical practice. Here, ERBB2 is linked to neoplasm.